CORESTEMCHEMON Inc. Overview
CorestemChemon is a small-cap Korean biotechnology company that combines two businesses with very different economics under one listed shell. The first is a cell-therapy franchise built around Neuronata-R (lenzumestrocel), an autologous bone-marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS) that has been sold in Korea since 2015 under a 2014 conditional approval. The second is a non-clinical contract research organisation (CRO), inherited from Chemon, which provides toxicology, pharmacokinetics, safety pharmacology and environmental toxicity testing and generates essentially all current revenue. The company's Phase 3 ALSummit trial missed its primary endpoint in the overall population but showed benefit in slow-progressing patients; Korea's MFDS approved a label modification in May 2026, keeping the product on the market. The investment case now hinges on restarting manufacturing, an FDA Type C meeting and a targeted 2027 US BLA filing, all funded from a thin balance sheet.
Company's own description
In company materials, CorestemChemon describes itself as a "total health care" company with a full drug-development cycle capability — from early non-clinical experiments through Phase 1–3 clinical development — combining a cell-therapy developer/manufacturer with Korea's first private non-clinical CRO [S25][S26]. Its corporate profile describes the biopharmaceuticals division as focused on rare and intractable diseases (ALS, lupus, neuromyelitis optica, multiple system atrophy) and the non-clinical CRO division as offering toxicity studies, pharmacokinetic analysis, safety pharmacology and environmental toxicity testing [S38].
Independent characterisation
In practice, CorestemChemon is a service business funding a single-asset biotech. The CRO division provides recurring (though cyclical) fee-for-service revenue; the biopharmaceutical division has contributed only low single-digit percentages of revenue even when Neuronata-R was in production — 4.41% of revenue (KRW 1.3 bn) in the first nine months of 2023 and KRW 0.6 bn of KRW 15.5 bn in H1 2024 [S31][S30]. Since Q1 2025, Neuronata-R manufacturing has been suspended pending a new manufacturing site certification and the MFDS license modification, so Q2 2026 revenue was 100% non-clinical CRO services [S9][S1].
Revenue model mix
| Revenue stream | Model | Weight (latest disclosed) | Notes |
|---|---|---|---|
| Non-clinical CRO services | Project-based contract research; revenue recognised by percentage of completion | ~100% of Q2 2026 revenue | Contract backlog in progress at 30 Jun 2026: KRW 27.15 bn total, of which KRW 14.46 bn already recognised [S8] |
| Neuronata-R (product sales) | Per-patient autologous manufacturing and supply to hospitals | ~0% since Q1 2025 (production halted) | Historically ~4% of revenue [S30][S31] |
| Licensing / royalties | None disclosed | 0% | No out-licensing revenue disclosed |
| Subscription | — | 0% | — |
Value-chain position
Cell therapy: vertically integrated — R&D, clinical development, GMP manufacturing (Yongin plant; new Osong plant), and supply. Because the product is autologous, each dose begins with a bone-marrow harvest from the patient, followed by cell culture and intrathecal injection; the product's expiry is 48 hours after manufacture [S42].
CRO: upstream service provider to pharmaceutical, biotech, health-functional-food and cosmetics-ingredient developers, and to government-funded research projects [S8][S9].
Customer types and end-markets
| Business | Customer types | End-markets |
|---|---|---|
| Neuronata-R | ALS patients treated through Korean hospitals; prospectively foreign patients travelling to Korea from 2027 [S17] | Rare neurodegenerative disease (ALS/MND) |
| Non-clinical CRO | Korean pharma/biotech sponsors; national R&D projects; functional food and cosmetics-material developers [S8][S9] | Drug development outsourcing (preclinical) |
Strategy
Stated strategic themes (paraphrased from company communications)
-
Keep Neuronata-R available in Korea and restart supply — the May 2026 MFDS decision is framed as preserving a cell-based option for the patients most likely to benefit, with full-scale production targeted for early 2027 [S17].
-
Precision positioning in slow-progressing ALS, supported by NfL biomarker data, as the basis for regulatory discussions [S20][S17].
-
US entry via a staged regulatory path: FDA Type C meeting → RMAT designation → BLA filing targeted for 2027 [S14][S16].
-
Real-world evidence generation, including treatment of foreign patients travelling to Korea [S17][S18].
-
CRO recovery and diversification into functional foods, cosmetics materials and next-generation (organoid/transcriptomics) testing [S9][S4b].
Initiatives in the last 24 months
| Initiative | Date | Detail | Source |
|---|---|---|---|
| Phase 3 subgroup strategy | May 2025 onward | Slow-progressor analysis used for MFDS and FDA discussions | [S19] |
| ATG Lifetech partnership | Jul 2025 | Transcriptomics-powered, organoid-based preclinical testing | [S4b] |
| Rights offering | Aug–Nov 2025 | KRW 26.1 bn; debt repayment and working capital | [S12][S13] |
| Osong plant licensing | Dec 2025 / May 2026 | Manufacturing licence change; cell processing facility licence | [S15] |
| NSF Piedmont Triad Regenerative Medicine Engine | Dec 2025 | First Korean company admitted; US operations moved to North Carolina | [S18][S17] |
| FDA Type C meeting | Aug 2026 | Nine discussion items incl. Phase 3 interpretation and BLA strategy | [S16] |
Medium-term targets / guidance
No quantitative financial guidance is published. Qualitative milestones: Type C meeting expected before end-October 2026; full-scale Neuronata-R production early 2027; US BLA filing in 2027; CRO revenue recovery in H2 2026 [S16][S17][S8]. ESG commitments: not publicly disclosed.
Products & Services
Biopharmaceutical Division
| Attribute | Detail | Source |
|---|---|---|
| Type | Autologous bone-marrow-derived mesenchymal stem cell (MSC) therapy | [S17] |
| Indication | Slowing progression of ALS (Lou Gehrig's disease) | [S16] |
| Administration | Intrathecal injection | [S17][S42] |
| Proposed mechanism | Paracrine action: anti-inflammatory factors (TGF-β1, IL-4, IL-10) dampening neuroinflammation; neuroprotective factors (VEGF, BDNF, IGF) supporting neuronal survival | [S17] |
| Shelf life | 48 hours from manufacture; a refrigerated preservative extending storage from 2 to 7 days was tested around 2020 | [S42][S35] |
| Regulatory status — Korea | Conditional approval 2014; launched Feb 2015; license modification reflecting Phase 3 data approved by MFDS in May 2026, keeping the product on the market | [S17][S26] |
| Regulatory status — US/EU | FDA Orphan Drug (2018); EMA Orphan Drug (2019); FDA Type C meeting requested Aug 2026; BLA targeted for 2027 | [S17][S16] |
| Patients treated | More than 400 in Korea | [S17][S21] |
| Manufacturing | Yongin GMP plant (utilisation 16.8% in 2024, 1.4% in 2025); new Osong plant licensed Dec 2025 (manufacturing change) and May 2026 (cell processing facility) | [S9][S15] |
| Supply status | Production suspended since Q1 2025; full-scale production expected early 2027 | [S9][S17] |
| Pricing | Not publicly disclosed. The company sought national health insurance listing via price negotiation around 2018 | [S43] |
(a) Neuronata-R® Inj. (lenzumestrocel) — commercial (Korea)
Clinical evidence summary
Phase 2 (NCT01363401): 64 participants, 1:1 randomised; two injections slowed ALSFRS-R decline versus control for at least six months [S21][S42].
Phase 3 ALSummit (NCT04745299): double-blind, randomised, placebo-controlled, multicentre; 115 participants; three arms (two Neuronata-R injections followed by three placebo injections; five Neuronata-R injections; five placebo injections) [S21][S42]. Primary endpoint CAFS (Combined Assessment of Function and Survival) was not met in the intent-to-treat population [S21]. In the slow-progressor subgroup, the therapy met CAFS and the ALSFRS-R secondary endpoint, with consistent improvement in slow vital capacity and lower neurofilament light chain (NfL) [S17]. The ALS/MND international alliance characterised the top-line data as not suggesting a strong clinical benefit [S42].
(b) CS20AT04 (MSC therapy) — lupus nephritis / SLE
Phase 1 safety study (NCT03174587) ran from May 2017 to August 2019; a long-term follow-up (NCT04522505) completed in July 2024 [S23]. The 2024 IR deck lists a lupus programme (coded CE211AT15) as Phase 1 completed [S25]. No Phase 2 start was identified.
(c) CS10BR05 — multiple system atrophy (MSA)
Listed by GlobalData as a Phase 1 programme [S37]. The 2024 IR deck lists an MSA programme (coded CE111BR16) with a Phase 1 plan submitted [S25]. Note: product codes differ between sources.
(d) HYNR-CS-Allo — allogeneic (HLA-haploidentical) bone-marrow MSC
Intrathecal allogeneic MSC therapy under development for MSA, cerebellar ataxia/spinocerebellar ataxia and ALS; Phase 1 per GlobalData [S37].
(e) Earlier-disclosed / exploratory indications
Neuromyelitis optica (NMO) [S38]; anoxic brain injury (ABI) and refractory epilepsy (cited in 2020 broker research) [S36]. The 2024 Korea IR Council report counted seven pipeline programmes including Neuronata-R [S26].
(f) In-licensing (historical)
Non-clinical CRO Division
| Service line | Description | Target customer | Source |
|---|---|---|---|
| Toxicology studies | GLP general and specialised toxicity studies required for IND submissions | Pharma/biotech sponsors | [S38] |
| Pharmacokinetics | PK analysis and bioanalysis | Pharma/biotech | [S38] |
| Safety pharmacology | Core battery safety pharmacology | Pharma/biotech | [S38] |
| Environmental toxicity | Environmental/ecotoxicity testing | Chemical and industrial clients | [S38] |
| Organoid / transcriptomics-based preclinical testing | Developed with ATG Lifetech (July 2025 partnership) | Next-generation therapeutics developers | [S4b] |
| Functional food and cosmetics material testing | Diversification beyond pharmaceuticals | Food and cosmetics ingredient developers | [S9] |
| Government projects | National R&D project testing | Public research programmes | [S8] |
Pricing: project-based; not publicly disclosed.
Financial Narrative
All figures are K-IFRS consolidated, fiscal years ending 31 December, sourced from DART-derived aggregators [S1][S2][S4][S5] unless stated.
Income statement
Revenue CAGR FY2021–FY2025: approximately −9.6% per year (computed). Margins computed from the rounded figures above.
Ten-year revenue and operating income history
Source: [S2]. The company has recorded operating losses every year since FY2016 [S2][S31].
Trailing-twelve-month trend (quarterly roll)
Source: [S4]. H1-2026 revenue KRW 9.7 bn and operating loss KRW 10.2 bn [S8].
Balance sheet
Source: [S5]. At 31 March 2026: total assets KRW 105.6 bn; current assets KRW 10.9 bn; cash KRW 2.8 bn [S5].
Cash has never exceeded KRW 3 bn at a year-end in the period shown, meaning the company operates hand-to-mouth, funding losses through treasury-share monetisation (2023 EBs, 2024 sales) and, in 2025, a rights offering.
Trend commentary
-
Revenue then fell for three consecutive years.
-
CRO cyclicality. Management attributes the CRO decline to the global downturn and a prolonged slump in Korean biotech funding, which reduced outsourced testing orders [S9].
-
Neuronata-R suspension. Production halted from Q1 2025; the company identified this as the main driver of H1-2025 revenue decline, though product revenue was already small [S10].
-
Cost structure. Revenue fell below cost of revenue in 2025, meaning negative gross profit; meanwhile R&D and SG&A rose, widening operating losses [S9][S10].
-
Inflection signal. H1-2026 new CRO orders of KRW 15.2 bn were 69% above H1-2025 (KRW 9.0 bn); management expects revenue recognition to accelerate in H2 2026 [S8].
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Segment (KRW Bn) | H1-2024 | H1-2025 | H1-2026 |
|---|---|---|---|
Total revenue | 15.5 | 11.6 | 9.7 |
Non-clinical CRO revenue | 14.9 | 11.3 | 9.7 |
Biopharmaceutical (Neuronata-R) revenue | 0.6 | 0.3 | 0.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (%) and Segment Margins & Growth (%)
| Metric (%) | H1-2024 | H1-2025 | H1-2026 |
|---|---|---|---|
CRO share of total revenue | 96.1 | 97.4 | 100.0 |
CRO revenue YoY growth | 0 | -24.2 | -14.2 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 30.2 | 46.3 | 33.7 | 28.8 | 20.2 |
Operating income (KRW Bn) | -10.5 | -6.0 | -19.7 | -22.0 | -21.2 |
Net income (KRW Bn) | -5.0 | 1.0 | -17.7 | -26.3 | -26.8 |
Revenue growth YoY (%) | 14.7 | 53.1 | -27.3 | -14.5 | -29.9 |
Operating margin (%) | -34.8 | -13.0 | -58.5 | -76.4 | -105.0 |
Net margin (%) | -16.6 | 2.2 | -52.5 | -91.3 | -132.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 18.0 | 18.1 | 22.3 | 24.3 | 26.4 | 30.2 | 46.3 | 33.7 | 28.8 | 20.2 |
Operating income (KRW Bn) | -1.6 | -5.1 | -4.0 | -5.1 | -7.0 | -10.5 | -6.0 | -19.7 | -22.0 | -21.2 |
Income Statement (TTM-Mar2025–TTM-Mar2026)
| Metric | TTM-Mar2025 | TTM-Jun2025 | TTM-Sep2025 | TTM-Dec2025 | TTM-Mar2026 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 26.5 | 24.8 | 20.1 | 20.2 | 18.4 |
Operating income (KRW Bn) | -23.4 | -24.1 | -25.9 | -21.2 | -23.3 |
Financial Analysis
| Metric | Status |
|---|---|
Gross profit | Negative in 2025; TTM to Sep 2025 approx. −KRW 4.0 bn (cost of revenue KRW 24.1 bn vs revenue KRW 20.1 bn) [S7]. |
EPS (basic/diluted) | TTM to Sep 2025: approx. −KRW 291 per share [S7]. |
Dividends per share | Zero; no dividends paid (dividend yield 0%) [S6] |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (KRW Bn) | 77.1 | 78.6 | 117.5 | 112.4 |
Current assets (KRW Bn) | 15.2 | 10.7 | 15.8 | 17.0 |
Cash and cash equivalents (KRW Bn) | 2.1 | 2.3 | 1.3 | 2.3 |
Additional Balance-sheet Data Point Details
| Additional balance-sheet data point | Value |
|---|---|
Total liabilities, 31 Dec 2024 | KRW 68.9 bn |
Total equity, 31 Dec 2024 | KRW 48.6 bn |
Short-term borrowings, 30 Jun 2024 | KRW 3.0 bn |
Current portion of long-term borrowings, 30 Jun 2024 | KRW 4.2 bn |
Accumulated deficit, 30 Jun 2024 | KRW 92.3 bn |
Cash (incl. other current assets), 30 Jun 2024 | KRW 1.9 bn |
Cash incl. short-term financial instruments, 30 Sep 2023 | KRW 8.0 bn |
Goodwill (Chemon) | KRW 3.9 bn, fully impaired in FY2025 |
Short-term liabilities vs cash (FY2025) | Short-term liabilities exceed cash on hand |
Implied book equity, Oct 2026 | ≈KRW 45 bn (derived: market cap KRW 107.1 bn ÷ P/B 2.37) |
Valuation Snapshot
| Metric | Value |
|---|---|
Operating cash flow H1-2025 | −KRW 7.8 bn |
R&D expense H1-2024 | KRW 5.4 bn (34% of revenue) |
Treasury share sales 2024 | KRW 10.4 bn |
Rights offering Nov 2025 (gross) | KRW 26.1 bn; KRW 19.1 bn earmarked for repaying 3rd and 4th series EBs |
Dividends paid / buybacks | None paid; no buyback programme identified |
Financial Analysis — ROE
| Ratio | Value | Basis / Source |
|---|---|---|
ROE | −66.4% (Valueline, Q1-2026 basis) vs −48.2% (StockHub, Oct 2026) | Discrepancy reflects differing periods/equity bases [S4][S6] |
P/B | 2.37 (Oct 2026); 1.84 (31 Jul 2026) | [S6][S4] |
Debt/equity FY2024 (total liabilities/equity) | 1.42x (computed: 68.9/48.6) | [S39] |
Net debt/EBITDA | Not meaningful (negative EBITDA) | — |
Revenue by Region
| Metric | TTM-Mar2025 | TTM-Jun2025 | TTM-Sep2025 | TTM-Dec2025 | TTM-Mar2026 |
|---|---|---|---|---|---|
Total revenue (KRW Bn) | 26.5 | 24.8 | 20.1 | 20.2 | 18.4 |
Domestic revenue (KRW Bn) | 26.5 | 24.8 | 20.2 | 20.2 | 18.4 |
Share Price & Returns
| Date | Close (KRW) |
|---|---|
Jan 2023 | EB exchange price set at 8,870 |
13 Oct 2025 | 1,647 |
22 Oct 2025 | 1,680 |
31 Jul 2026 | 1,809 |
~14 Oct 2026 | 2,025 |
52-week range (to Oct 2026) | 1,014 – 6,100 |
Valuation Multiples
| Multiple | CorestemChemon | Note |
|---|---|---|
P/E | Not meaningful (losses) | [S6] |
P/B | 2.37 | [S6] |
EV/Sales | ≈5x (market cap KRW 107 bn / FY2025 revenue KRW 20.2 bn, ignoring net debt) | Computed |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None (zero covering reports) |
Dividend history / policy | No dividends |
Buyback authorisations | None identified; treasury shares have been sold, not bought |
Debt instruments | 2nd and 3rd series EBs (Jan 2023, KRW 32.3 bn); 3rd and 4th series repaid with 2025 rights proceeds (KRW 19.1 bn) |
Analyst Conclusions
Management guidance (qualitative)
-
FDA Type C meeting expected before end-October 2026; written minutes within 30 days of the meeting [S16].
-
Full-scale Neuronata-R production and treatment resumption in early 2027 [S17].
-
US BLA filing targeted for 2027 [S16][S17].
-
CRO revenue recovery in H2 2026 on conversion of H1 orders [S8].
Consensus growth expectations: none available.
Bull case
-
Regulatory de-risking in Korea is done. The May 2026 MFDS approval removes the immediate risk of market withdrawal and, with Osong licensed, revenue can restart in 2027 [S17][S15].
-
CRO is turning. H1-2026 orders rose 69% to KRW 15.2 bn and the in-progress contract book is KRW 27.15 bn; given operating leverage, even moderate revenue recovery would narrow losses materially [S8].
-
Option value in the US. A constructive Type C outcome on a slow-progressor, NfL-supported label could support RMAT and a 2027 BLA, which would be transformative relative to a ≈KRW 107 bn market cap [S16][S6].
Bear case
-
The pivotal trial failed. Subgroup and biomarker arguments may not satisfy FDA, and the Relyvrio episode makes regulators cautious [S21][S33].
-
Funding gap. Year-end cash of KRW 2.3 bn (FY2025) against annual operating losses above KRW 20 bn implies further equity issuance before any US revenue [S5][S2].
-
Product economics are small. Even at full production, Neuronata-R historically generated around 4% of revenue (≈KRW 1–2 bn per year), raising doubt that Korean sales alone can fund the company [S30][S31].
Catalysts and monitorables (next 12 months)
-
FDA Type C meeting minutes (expected Q4 2026).
-
Q3-2026 report (mid-November 2026): CRO revenue conversion and gross margin.
-
Osong comparability evaluation and production restart timeline.
-
Any new equity or debt financing.
-
RMAT application/designation.
-
FY2026 annual report (March 2027): pre-tax loss vs equity for KOSDAQ listing-maintenance tests.
-
First foreign-patient treatments in Korea (2027).
Analyst verdict
CorestemChemon is best understood as a distressed CRO carrying a high-risk regulatory option on an ALS cell therapy. The CRO, inherited through the 2022 Chemon merger, generates all current revenue but has shrunk from KRW 46.3 bn in FY2022 to KRW 20.2 bn in FY2025, slipped into negative gross profit, and forced a full write-off of the goodwill created by the merger. The cell-therapy business has produced only marginal revenue historically and none since early 2025, while its pivotal Phase 3 trial missed its primary endpoint in the overall population.
Against that, 2026 has delivered genuine progress. The MFDS kept Neuronata-R on the Korean market after reviewing Phase 3 data, the Osong plant has the licences needed to restart supply, and CRO order intake has recovered sharply. The company has also built credible US scaffolding through NSF/WFIRM membership and a pending FDA Type C meeting.
The central analytical problem is that the two halves of the business do not fund each other. The CRO cannot cover group operating losses of roughly KRW 21 bn a year, and Korean Neuronata-R sales are too small to close the gap. The equity story therefore rests almost entirely on the FDA's response to a post-hoc subgroup argument — an argument regulators have historically treated cautiously, and one sharpened by the Relyvrio withdrawal. Even a constructive meeting is more likely to yield a request for additional confirmatory evidence than a direct path to approval, which would require capital the company does not have.
At roughly 5x trailing sales and 2.4x book with no analyst coverage, the valuation embeds meaningful optionality on the US pathway. The investment profile is binary and financing-dependent: the FDA minutes and the next funding event will determine outcomes far more than operating results.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Notes |
|---|---|---|
Yang Gil-an (양길안) | Representative Director / Chairman (registered executive) | Listed as representative in 2024 IR and FY2025-based company data; holds 8,757 shares after Oct 2025 rights allotment |
Kim Kyung-suk (김경숙) | Founder; largest shareholder (6.49%) | Former CEO of CORESTEM (named CEO in 2018–2020 press); some vendors still list her as CEO — discrepancy flagged |
Kwon Kwang-soon (권광순) | President (사장) | Held 0.83–0.93% in specified securities in Oct 2025; subscribed KRW 6.7 bn of the 2023 3rd-series EB |
Kim Moon-soon (김문순) | Director (reported as both 이사 and non-registered executive) | 0.01% |
Gil Ki-hyun (길기현) | Managing Director (non-registered) | 0.11% |
Ryung-A Lee | Head of R&D Innovation | Presented at PACTALS 2025 |
Major Shareholders
| Holder | Stake |
|---|---|
Kim Kyung-suk (largest shareholder, own stake) | 6.49% |
Treasury shares | ≈4.78% |
Kwon Kwang-soon | ≈0.14% common shares (0.83% incl. rights, Oct 2025) |
Minority shareholders (28,190 holders) | 79.25% |
Competitive Landscape
Key Competitors
| Competitor | Product / approach | Status (as known) | Relative positioning |
|---|---|---|---|
Mitsubishi Tanabe Pharma | Edaravone (Radicava / Radicava ORS) | Approved in multiple markets | Established standard-of-care adjunct |
Riluzole (originator Sanofi; generics) | Glutamate modulator | Approved globally; generic | Baseline therapy |
Biogen / Ionis | Tofersen (Qalsody) for SOD1-ALS | FDA accelerated approval 2023 (NfL-based) | Precedent for NfL as a surrogate — relevant to CorestemChemon's argument |
Amylyx | Relyvrio | Approved in the US in Sept 2022 on Phase 2 data; withdrawn in 2024 after Phase 3 failure; Korean press cites ≈KRW 550 bn in sales over ~14 months [S33] | Cautionary precedent for approval on weak pivotal data |
BrainStorm Cell Therapeutics | NurOwn (autologous MSC-NTF) | US Phase 3 failed primary endpoint (2020) [S36] | Closest cell-therapy analogue |
Kadimastem | AstroRx (astrocyte cells) | Early clinical | Former prospective partner [S34] |
Key Competitors — Korea Institute of Toxicology
| Competitor | Profile | Data point |
|---|---|---|
Korea Institute of Toxicology (KIT) | Government-funded GLP toxicology institute | — |
Biotoxtech (KOSDAQ 086040) | Founded Aug 2000; Cheongju-based non-clinical CRO; AI-assisted pathology | — |
DT&CRO (KOSDAQ 383930) | Full-service CRO (efficacy, non-clinical, Phase 1); listed Nov 2022 | H1-2025 revenue KRW 20.2 bn (+46% YoY); market cap ≈KRW 34.6 bn (late 2025) |
Woojung Bio, CNR Research, Dream CIS | Korean CRO peers (preclinical/clinical) | — |
Charles River Laboratories, Inotiv, WuXi AppTec | Global preclinical CROs | — |
Peer Comparison FY2025
| Metric | CorestemChemon | DT&CRO |
|---|---|---|
H1-2025 revenue (KRW Bn) | 11.6 | 20.2 |
H1-2025 revenue growth YoY (%) | -25 | 46 |



